Your shopping cart is currently empty

PTPN2/1-IN-4 (Compound WS35) is an orally active dual inhibitor of PTPN1 and PTPN2, with IC50 values of 12.8 nM and 5.8 nM, respectively. It modulates the IFNγ-JAK-STAT signaling pathway and significantly enhances CD8+ T cell tumor infiltration. PTPN2/1-IN-4 demonstrates potent anticancer activity, effectively inhibiting tumor growth in the B16-OVA syngeneic mouse model both as a monotherapy and in combination with anti-PD-1 antibody treatment.
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
| Description | PTPN2/1-IN-4 (Compound WS35) is an orally active dual inhibitor of PTPN1 and PTPN2, with IC50 values of 12.8 nM and 5.8 nM, respectively. It modulates the IFNγ-JAK-STAT signaling pathway and significantly enhances CD8+ T cell tumor infiltration. PTPN2/1-IN-4 demonstrates potent anticancer activity, effectively inhibiting tumor growth in the B16-OVA syngeneic mouse model both as a monotherapy and in combination with anti-PD-1 antibody treatment. |
| Molecular Weight | 422.48 |
| Formula | C19H23FN4O4S |
| Cas No. | 3093350-55-8 |
| Smiles | O=C1NS(=O)(=O)N(C2=C(F)C=C(C=C2O)C=3C=NC(NCCC(C)C)=C(C3)C)C1 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.